CERTOLIZUMAB PEGOL PERSISTENCE AND ADHERENCE BY DRUG FORMULATION, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, OR RHEUMATOID ARTHRITIS

被引：0
|
作者：
Beaty, S. [1 ]
Zichlin, M. L. [2 ]
Hopson, S. [1 ]
Devine, F. [2 ]
Pi, S. [2 ]
Moore, J. [3 ]
Swallow, E. [2 ]
机构：
[1] UCB Pharma, Smyrna, GA USA
[2] Anal Grp Inc, Boston, MA USA
[3] Mercer Univ, Coll Pharm, Atlanta, GA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR106
引用
收藏
页码：S561 / S561
页数：1
相关论文
共 50 条
  • [21] Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials
    Curtis, Jeffrey R.
    Mariette, Xavier
    Gaujoux-Viala, Cecile
    Blauvelt, Andrew
    Kvien, Tore K.
    Sandborn, William J.
    Winthrop, Kevin
    de Longueville, Marc
    Huybrechs, Ivo
    Bykerk, Vivian P.
    RMD OPEN, 2019, 5 (01):
  • [22] Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Florenzo Iannone
    Angelo Semeraro
    Giorgio Carlino
    Leonardo Santo
    Romano Bucci
    Laura Quarta
    Nicola Maruotti
    Carmelo Zuccaro
    Antonio Marsico
    Paola Chiara Francesca Falappone
    Daniela Mazzotta
    Francesco Paolo Cantatore
    Maurizio Muratore
    Giovanni Lapadula
    Clinical Drug Investigation, 2019, 39 : 565 - 575
  • [23] Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Iannone, Florenzo
    Semeraro, Angelo
    Carlino, Giorgio
    Santo, Leonardo
    Bucci, Romano
    Quarta, Laura
    Maruotti, Nicola
    Zuccaro, Carmelo
    Marsico, Antonio
    Falappone, Paola Chiara Francesca
    Mazzotta, Daniela
    Cantatore, Francesco Paolo
    Muratore, Maurizio
    Lapadula, Giovanni
    CLINICAL DRUG INVESTIGATION, 2019, 39 (06) : 565 - 575
  • [24] Health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with certolizumab pegol
    Sarobe, Maite
    Arrondo, Amaya
    Ibarrondo, Oliver
    Mar, Javier
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 27 - 30
  • [25] SERUM CALPROTECTIN AS A MARKER OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS
    Jarlborg, Matthias
    Courvoisier, Delphine
    Lamacchia, Celine
    Martinez-Prat, Laura
    Bentow, Chelsea
    Mahler, Michael
    Finckh, Axel
    Gabay, Cem
    Nissen, Michael
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1588 - 1588
  • [26] EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL WITH METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS
    Carlino, G.
    Cozzolongo, A.
    Maggio, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 1049 - 1049
  • [27] Catastrophizing in Patients with Axial Spondyloarthritis and Psoriatic Arthritis
    Coste, Baptiste
    Traverson, Charlotte
    Filhol, Elisabeth
    Benamar, Soraya
    Morel, Jacques
    Laurent-Chabalier, Sabine
    Combe, Bernard
    Daien, Claire
    Lukas, Cedric
    Hua, Charlotte
    Gaujoux-Viala, Cecile
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [28] Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis
    Esposito, Maria
    Carubbi, Francesco
    Giunta, Alessandro
    Alunno, Alessia
    Giacomelli, Roberto
    Fargnoli, Maria Concetta
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (02) : 119 - 128
  • [29] Certolizumab Pegol Therapeutic Range in Rheumatoid Arthritis
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (06) : 1278 - 1278
  • [30] Certolizumab pegol therapy of rheumatoid arthritis: Overview
    Zidi, Ines
    Mnif, Wissem
    Bouaziz, Aicha
    Ben Amor, Nidhal
    DRUG DEVELOPMENT RESEARCH, 2011, 72 (07) : 603 - 614
12345